- Trials with a EudraCT protocol (1,965)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (390)
1,965 result(s) found for: vaccine.
Displaying page 1 of 99.
| EudraCT Number: 2014-004252-60 | Sponsor Protocol Number: RTQ-15-TKU | Start Date*: 2014-12-16 |
| Sponsor Name:Vaccine Research Center, University of Tampere | ||
| Full Title: Shedding and immune response of rotavirus vaccine (RotaTeq) | ||
| Medical condition: Test subjects are healthy. | ||
| Disease: | ||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FI (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-003838-32 | Sponsor Protocol Number: ADC01 | Start Date*: 2019-01-11 |
| Sponsor Name:Sanofi Pasteur | ||
| Full Title: Safety and Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed (SP0173) in Healthy Adolescents, Adults, and Older Adults | ||
| Medical condition: Tetanus Diphtheria Pertussis | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2007-000164-24 | Sponsor Protocol Number: 109836 | Start Date*: 2007-05-21 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A phase I/II, partially-blind, randomized multicentre study to assess the safety and immunogenicity of an HPV-16/18/33/58 L1 VLP vaccine formulated with different adjuvant systems when administered... | ||
| Medical condition: Healthy volunteers | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2021-001993-52 | Sponsor Protocol Number: IMCOVAS | Start Date*: 2021-05-20 |
| Sponsor Name:University of Antwerp | ||
| Full Title: Assessment of the immunogenicity and safety of marketed vaccines for COVID-19 after regular schedule and adapted vaccine schedules and routes: BNT162b2 (Comirnaty®; Pfizer-BioNTech), mRNA-1273 Vacc... | ||
| Medical condition: Coronavirus disease-19 (COVID-19) | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: BE (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2011-001508-37 | Sponsor Protocol Number: 113681 | Start Date*: 2015-05-22 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: Phase III randomized, open, controlled study to evaluate the immune response to the hepatitis B antigen of the RTS,S/AS01E candidate vaccine, when administered as primary vaccination integrated int... | ||
| Medical condition: Healthy volunteers (Primary immunization against Plasmodium falciparum malaria, immunization against hepatitis B) | ||
| Disease: | ||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2006-002369-37 | Sponsor Protocol Number: GID23 | Start Date*: 2006-09-25 |
| Sponsor Name:Sanofi Pasteur SA | ||
| Full Title: Lot-to-Lot Consistency Study of the Investigational, Split-virion, Inactivated Influenza Vaccine, Administered by the Intradermal Route in Adults. | ||
| Medical condition: Vaccination of adults aged 18 to 60 years with inactivated, split-virion influenza vaccine administered by the intradermal route using Vaxigrip® as IM reference vaccine. | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: LT (Completed) ES (Completed) GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2016-001963-35 | Sponsor Protocol Number: MET50 | Start Date*: 2016-05-06 |
| Sponsor Name:Sanofi Pasteur Inc. | ||
| Full Title: A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents | ||
| Medical condition: Healthy volunteers (active immunization against invasive meningococcal disease (IMD) caused by Meningococcal serogroups A, C, Y or W | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2022-000623-21 | Sponsor Protocol Number: 218350 | Start Date*: 2022-09-21 |
| Sponsor Name:GlaxoSmithKline, S.A. | ||
| Full Title: A Phase III, open-label, randomized, controlled, multi-country study to evaluate the immune response, safety and reactogenicity of an RSVPreF3 OA investigational vaccine when co-administered with F... | ||
| Medical condition: Respiratory syncytial virus infection | ||
| Disease: | ||
| Population Age: Elderly | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) BE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2015-005189-48 | Sponsor Protocol Number: MPS01 | Start Date*: 2015-11-17 |
| Sponsor Name:Sanofi Pasteur SA | ||
| Full Title: Safety and Immunogenicity of Sanofi Pasteur Meningococcal (Groups A and C) Polysaccharide Vaccine versus Lanzhou Institute of Biological Products Meningococcal (Groups A and C) Polysaccharide Vacci... | ||
| Medical condition: Meningococcal Disease | ||
| Disease: | ||
| Population Age: Children, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2021-000307-20 | Sponsor Protocol Number: COMB157GDE01 | Start Date*: 2021-04-28 | |||||||||||
| Sponsor Name:Novartis Pharma Vertriebs GmbH | |||||||||||||
| Full Title: Tracking the immune response to SARS-CoV-2 modRNA vaccines in an open-label multicenter study in participants with relapsing multiple sclerosis treated with ofatumumab s.c. (KYRIOS) | |||||||||||||
| Medical condition: relapsing multiple sclerosis | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2004-004370-85 | Sponsor Protocol Number: 104083 | Start Date*: 2005-01-25 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A phase III, multicentric open study to evaluate the immunological memory induced by a 3-dose primary vaccination followed by a booster dose with GSK Biologicals’ 11-valent conjugate pneumococcal v... | ||
| Medical condition: A single dose of Aventis Pasteur’s 23-valent pneumococcal polysaccharide vaccine (Pneumo 23) to healthy children who were either primed with the 3-dose primary vaccination followed by the booster d... | ||
| Disease: | ||
| Population Age: Children, Under 18 | Gender: Male, Female | |
| Trial protocol: SK (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2017-004732-11 | Sponsor Protocol Number: | Start Date*: 2018-01-19 |
| Sponsor Name:University of Oxford | ||
| Full Title: Preventing meningitis in young people after infant immunisation: effect of a single meningococcal 4CMenB vaccine booster over 10 years of age | ||
| Medical condition: Meningococcus group B disease, which can cause a variety of symptoms. The most serious of these are meningitis, and septicaemia (also known as blood poisoning). | ||
| Disease: | ||
| Population Age: Children, Under 18 | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2021-003953-43 | Sponsor Protocol Number: VAC31518COV3005 | Start Date*: 2021-11-29 | ||||||||||||||||
| Sponsor Name:Janssen Vaccines & Prevention B.V. | ||||||||||||||||||
| Full Title: A Randomized, Double-blind, Phase 3 Study to Evaluate Safety, Reactogenicity, and Immunogenicity of Co-administration of Ad26.COV2.S and Influenza Vaccines in Healthy Adults 18 Years of Age and Older | ||||||||||||||||||
| Medical condition: Healthy Volunteers (Prevention of COVID-19 and influenza) | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: PL (Completed) BE (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2021-004016-26 | Sponsor Protocol Number: Clin_COVID-19_Corok | Start Date*: 2021-10-18 |
| Sponsor Name:Meilahti Vaccine Research Center - Helsinki University Hospital | ||
| Full Title: Substudy "Responses to Covid-19 vaccines" in research "Clinical picture, immunology, genetics and pathogenesis of COVID-19 infection" | ||
| Medical condition: None | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: FI (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2006-001934-42 | Sponsor Protocol Number: 107706 | Start Date*: 2006-07-26 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A phase IIIa open, randomised, controlled study to assess the safety, reactogenicity and immunogenicity induced by a booster dose of GlaxoSmithKline (GSK) Biologicals 10-valent pneumococcal conjuga... | ||
| Medical condition: Booster vaccination against Streptococcus pneumoniae and active immunization against measles, mumps, rubella and varicella diseases in children during the second year of life. | ||
| Disease: | ||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
| Trial protocol: FI (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2012-005243-25 | Sponsor Protocol Number: GID37 | Start Date*: 2013-04-16 | |||||||||||
| Sponsor Name:Sanofi Pasteur | |||||||||||||
| Full Title: Immunogenicity and Safety of the Trivalent Influenza Vaccine (Split-Virion, Inactivated), Northern Hemisphere 2013-2014 Formulation (Intradermal Route) | |||||||||||||
| Medical condition: Prophylaxis of influenza (2013-2014 Northern Hemisphere Season) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-007605-37 | Sponsor Protocol Number: 112807 | Start Date*: 2009-05-12 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A phase III, open, multicentre, extension study to assess the immune response following administration of an additional dose of GSK Biologicals’ 10-valent conjugate pneumococcal vaccine or Prevenar... | ||
| Medical condition: A single dose of either 10Pn-PD-DiT or Prevenar vaccine to healthy children previously primed with 3 primary doses of 10Pn-PD-DiT or Prevenar vaccine in study 10PN-PD-DIT-003 (105554) and a booster... | ||
| Disease: | ||
| Population Age: Children, Under 18 | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2021-004550-33 | Sponsor Protocol Number: APHP211184 | Start Date*: 2021-11-15 |
| Sponsor Name:Assistance publique Hopitaux de Paris/ DRCI | ||
| Full Title: Immunogenicity and reactogenicity following a booster dose of COVID-19 mRNA vaccine (Pfizer-BioNtech) and two adjuvanted sub-unit vaccines (SP/GSK) administered in adults who received 2 doses of Pf... | ||
| Medical condition: COVID-19 | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2008-008104-41 | Sponsor Protocol Number: 112801 | Start Date*: 2009-07-03 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A phase III long-term follow-up study to assess immunological memory induced following primary and booster vaccination with GSK Biologicals’ 10-valent pneumococcal conjugate vaccine (10Pn-PD-DiT), ... | ||
| Medical condition: Subjects aged 31-44 months previously vaccinated with GSK Biologicals’ 10Pn-PD-DiT vaccine and age-matched unprimed children who participated in study 10PN-PD-DIT-014 (107137). | ||
| Disease: | ||
| Population Age: Children, Under 18 | Gender: Male, Female | |
| Trial protocol: CZ (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2014-003514-91 | Sponsor Protocol Number: V59P10 | Start Date*: 2014-09-30 |
| Sponsor Name:Novartis Vaccines and Diagnostics S.r.l. | ||
| Full Title: A Phase 3, Randomized, Observer-blind, Controlled, Multi-Center Study to Compare the Safety of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine with that of a Licensed Meningococcal ACWY P... | ||
| Medical condition: Novartis Meningococcal ACWY Conjugate Vaccine is intended for prevention of meningitis and septicemia caused by Neisseria meningitidis A, C, W-135 and Y. | ||
| Disease: | ||
| Population Age: Children, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
